文献速递乳腺癌

乳腺癌治疗性疫苗:时机终于成熟了吗?

Therapeutic vaccines for breast cancer: Has the time finally come?
PubMed 文献 · Eur J Cancer · 2021-11-22

本综述回顾乳腺癌治疗性疫苗的过去与当前全景。免疫检查点抑制剂在乳腺癌中获益有限(三阴性乳腺癌部分亚型除外),免疫抑制性肿瘤微环境是重要原因。新抗原成为首选靶点,基因与病毒载体平台在研,脂质纳米颗粒具免疫原性且递送高效;作者提出癌前或辅助阶段单用疫苗、晚期联合免疫检查点抑制剂等策略。

要点

  • 免疫检查点抑制剂在乳腺癌中获益有限,三阴性乳腺癌部分亚型除外。
  • 免疫抑制性肿瘤微环境是乳腺癌免疫治疗应答不佳的重要因素。
  • 新抗原为治疗性疫苗首选靶点,基因与病毒载体平台在研,脂质纳米颗粒为具免疫原性且高效的递送载体。

核心结论

  • 经历近二十年临床试验结果不佳后,治疗性疫苗因技术进步及新冠疫情推动重回关注焦点;作者提出癌前或辅助阶段单用疫苗、晚期联合免疫检查点抑制剂等策略具有前景。

研究设计与样本

  • 综述,系统回顾乳腺癌治疗性疫苗的过去与当前全景。

主要发现

  • 免疫检查点抑制剂在乳腺癌中显示适度获益,三阴性乳腺癌部分亚型除外。
  • 乳腺癌中通常存在的免疫抑制性肿瘤微环境是免疫治疗应答不佳的重要因素。
  • 新抗原正成为治疗性疫苗的首选靶点,基因与病毒载体平台在研。
  • 脂质纳米颗粒被证明具免疫原性且为高效递送载体。
  • 既往治疗性疫苗临床试验重点关注转移性疾病,其肿瘤微环境更易受抑制机制影响。

关键数值与推荐

  • 作者提出在癌前或辅助阶段单用治疗性疫苗、在晚期疾病中建立联合治疗(如疫苗联合免疫检查点抑制剂)为有前景的策略。

临床怎么用

  • 作者提出在癌前或辅助阶段单用治疗性疫苗、在晚期疾病中建立联合治疗(如疫苗联合免疫检查点抑制剂)为有前景的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ability to exploit the immune system as a weapon against cancer has revolutionised the treatment of cancer patients, especially through immune checkpoint inhibitors (ICIs). However, ICIs demonstrated a modest benefit in treating breast cancer (BC), with the exception of certain subsets of triple-negative BCs. An immune-suppressive tumour microenvironment (TME), typically present in BC, is an important factor in the poor response to immunotherapy. After almost two decades of poor clinical trial results, cancer vaccines (CVs), an active immunotherapy, have come back in the spotlight because of some technological advancements, ultimately boosted by coronavirus disease 2019 pandemic. In particular, neoantigens are emerging as the preferred targets for CVs, with gene-based and viral vector-based platforms in development. Moreover, lipid nanoparticles proved to be immunogenic and efficient delivery vehicles. Past clinical trials investigating CVs focused especially on the metastatic disease, where the TME is more likely compromised by inhibitory mechanisms. In this sense, favouring the use of CVs as monotherapy in premalignant or in the adjuvant setting and establishing combination treatments (i.e. CV plus ICI) in late-stage disease are promising strategies. This review provides a full overview of the past and current breast cancer vaccine landscape.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Corti C, Giachetti PPMB, Eggermont AMM, et al. Therapeutic vaccines for breast cancer: Has the time finally come? Eur J Cancer. 2021. PMID: 34823982. doi:10.1016/j.ejca.2021.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。